Sun Pharmaceutical Industries is currently trading at Rs. 606.25, up by 2.00 points or 0.33% from its previous closing of Rs. 604.25 on the BSE.
The scrip opened at Rs. 610.00 and has touched a high and low of Rs. 610.00 and Rs. 602.45 respectively. So far 93403 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 610.00 on 05-Jan-2021 and a 52 week low of Rs. 315.20 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 610.00 and Rs. 581.70 respectively. The current market cap of the company is Rs. 144979.82 crore.
The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.83% and 12.48% respectively.
Sun Pharmaceutical Industries has initiated Phase 2 clinical trial for SCD-044 (a novel, orally bioavailable sphingosine-1-phosphate (S1P) receptor 1 agonist) in patients with moderate to severe plaque psoriasis.
The Phase 2 study is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SCD-044 in the treatment of moderate to severe plaque psoriasis. The study will enroll approximately 240 subjects and top line results are expected in 2022. SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis, are also expected to be initiated soon.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |